Daxor’s Blood Volume Analysis Metric Validated as Uniquely Accurate Versus Capillary Leak Indexes in New Clinical Data Presented at SCCM 2026

Rhea-AI Summary

Daxor (Nasdaq: DXR) presented clinical data at SCCM 2026 showing its Blood Volume Analyzer (BVA) directly measures Albumin Escape Rate (AER) and detects capillary leak with higher mechanistic specificity than common clinical indices.

Key result: BVA identified a median 20% per hour albumin escape rate in patients while traditional scores remained uniformly low, suggesting clinical indices may miss significant vascular leak.

Positive

• BVA measured median 20%/hour albumin escape rate
• Direct, real-time leak metric expands critical care and heart failure diagnostics

Negative

• Clinical indices showed weak, non-significant correlation with actual albumin escape
• Traditional scores may miss significant vascular leakage in heart failure

Key Figures

Albumin escape rate: median 20% per hour

1 metrics

Albumin escape rate median 20% per hour Elevated albumin leak detected by BVA despite low traditional scores in heart failure cohort

Market Reality Check

Price: $10.39 Vol: Volume 14,581 is 11% abov...

normal vol

$10.39 Last Close

Volume Volume 14,581 is 11% above the 20-day average of 13,170, indicating modestly elevated interest ahead of this update. normal

Technical Shares at $10.39 are trading below the 200-day MA of $11.63 and about 29.6% under the 52-week high.

Peers on Argus

DXR is up 1.56% while peers show mixed moves: AKYA -8.51%, PDEX -4.22%, MLSS -1....

DXR is up 1.56% while peers show mixed moves: AKYA -8.51%, PDEX -4.22%, MLSS -1.48%, ZJYL -1.79%, and ZTEK +2.32%, pointing to a stock-specific reaction rather than a sector-wide trend.

Previous Clinical trial Reports

1 past event · Latest: Sep 30 (Positive)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Sep 30	Clinical data + launch	Positive	+6.2%	Unveiled FDA-cleared next-gen BVA analyzer and pivotal validation data at HFSA.

Pattern Detected

Prior clinical-trial-tagged news produced a positive price reaction, suggesting that clinically validating BVA technology has previously aligned with favorable market responses.

Recent Company History

Recent history shows Daxor emphasizing clinical validation and deployment of its Blood Volume Analyzer. A prior clinical trial-tagged update on Sep 30, 2025 at HFSA highlighted pivotal data and an FDA-cleared next-generation BVA analyzer, prompting a 6.21% gain. Today’s SCCM 2026 data further validate BVA’s mechanistic specificity versus capillary leak indices, extending the narrative of growing clinical support for the technology in critical care and heart failure settings.

Historical Comparison

+6.2% avg move · Past clinical data events for DXR, such as HFSA 2025, saw an average move of 6.21%. The new SCCM 202...

clinical trial

+6.2%

Average Historical Move clinical trial

Past clinical data events for DXR, such as HFSA 2025, saw an average move of 6.21%. The new SCCM 2026 validation similarly reinforces BVA’s accuracy and critical-care relevance.

Clinical evidence has progressed from pivotal HFSA studies validating BVA accuracy and outcomes to SCCM 2026 data confirming mechanistic specificity for capillary leak detection in heart failure.

Market Pulse Summary

This announcement highlights new SCCM 2026 data showing that Daxor’s BVA can detect elevated albumin...

Analysis

This announcement highlights new SCCM 2026 data showing that Daxor’s BVA can detect elevated albumin escape rates, with a median 20% per hour, even when traditional scores remain low. It extends prior HFSA 2025 evidence that validated BVA’s accuracy and clinical impact. Investors may watch for additional studies in inflammatory conditions like sepsis, as well as real-world adoption in ICUs and heart failure programs, to gauge how this validation translates into commercial traction.

Key Terms

edema, icu, sepsis, ards

4 terms

edema medical

"allowing fluid and proteins to escape ... into the surrounding tissue (edema)."

Edema is the buildup of excess fluid in body tissues that causes visible swelling, like a sponge or water balloon filling up where it shouldn't. For investors, edema matters because it can be a side effect that affects patient safety, clinical trial results, treatment costs, regulatory approval, and public perception of healthcare products or services, all of which can influence a company’s financial outlook.

icu medical

"This condition is a primary driver of organ failure in the ICU, yet clinicians have"

An ICU, or intensive care unit, is a hospital ward equipped and staffed to monitor and treat patients with life‑threatening illnesses or injuries that require constant attention and advanced medical support, like breathing machines or continuous medication. For investors, ICU capacity and related costs matter because high demand can signal increased use of hospital services, drive revenue for medical device and healthcare providers, strain a facility’s resources and margins, and influence regulatory and reimbursement pressures—similar to how a factory’s production line affects a manufacturer’s output and costs.

sepsis medical

"Capillary leak is something we constantly see in sepsis, ARDS, and trauma"

Sepsis is a dangerous medical condition in which an infection triggers the body's defenses to damage its own tissues and organs, often leading to organ failure and emergency hospital care. For investors it matters because sepsis drives demand for diagnostics, antibiotics, intensive-care treatments and hospital resources, affects healthcare costs and insurer payouts, and can influence the commercial prospects and valuation of companies developing related tests, drugs and devices.

ards medical

"Capillary leak is something we constantly see in sepsis, ARDS, and trauma"

Acute respiratory distress syndrome (ARDS) is a sudden, severe failure of the lungs where fluid and inflammation prevent oxygen from getting into the bloodstream, like heavy wet balloons that won’t inflate properly. It matters to investors because ARDS represents a serious unmet medical need that drives demand for new therapies, influences clinical trial size and risk, affects regulatory scrutiny and reimbursement, and can significantly impact the valuation of companies developing treatments or diagnostics.

AI-generated analysis. Not financial advice.

OAK RIDGE, TN, March 26, 2026 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces that new clinical data evaluating the accuracy of capillary leak detection scores compared to BVA was presented at the Society for Critical Care Medicine (SCCM) 2026 Critical Care Congress.

The study, titled, "Mechanistic Specificity of Capillary Leak Indices: Validation in Heart Failure as a Negative Control," was featured during the Research Snapshot Theater. The research investigated the relationship between traditional clinical scoring methods and direct, in-vivo measurement of albumin escape using Daxor’s Blood Volume Analyzer (BVA).

The "Unmet Need": Identifying the Hidden Leak

Capillary leak occurs when the walls of the blood vessels become permeable, allowing fluid and proteins to escape from the bloodstream into the surrounding tissue (edema). This condition is a primary driver of organ failure in the ICU, yet clinicians have historically lacked a "gold standard" to measure it at the bedside.

“Capillary leak is something we constantly see in sepsis, ARDS, and trauma, and we know it drives morbidity and mortality,” said Jonathan Popham, MD, lead researcher from Children’s National Hospital. “But the uncomfortable truth is we don't have validated, reproducible data to measure it. If we can't measure it, how do we study it or know if our interventions work?”

Study Findings: BVA vs. Traditional Clinical Scores

The study utilized Daxor’s BVA system to measure the Albumin Escape Rate (AER)—the actual fraction of intravascular albumin leaking across the capillary wall per hour. Researchers compared these direct measurements against four common clinical indices (including the Capillary Leak Index and SOFA score) in a heart failure cohort.

Key findings include:

• Superior Detection: The BVA system identified significantly elevated albumin escape rates (median 20% per hour) in patients, even when traditional clinical scores remained “uniformly low.” The researcher Dr. Popham noted that “BVA provides a level of mechanistic specificity that traditional scores simply cannot match”
• Direct vs. Estimated Data: Clinical indices showed weak and non-significant correlations with actual albumin escape, suggesting that these common scores may miss significant vascular leakage in the arena of heart failure, considered a non-inflammatory setting
• Mechanistic Specificity: The research confirms that while common clinical scores are designed to detect inflammatory leak (like sepsis), their actual accuracy remains unproven. Daxor’s BVA is the only tool capable of directly measuring albumin leak, including patients with heart failure and sepsis, filling a critical diagnostic gap. Future proposed studies intend to show whether clinical scores are valid in inflammatory leak, or whether in that domain as well, only Daxor’s technology remains the reliable metric of direct measurement of a high albumin leak rate
  
  

Commercial Significance

This data reinforces Daxor’s position as the sole provider of objective, real-time albumin leak rate as well as volume measures. The unique combination of highly accurate and direct volume measurement and leak rate analysis expands the clinical benefit of the test deep into the critical care and heart failure markets, where differentiating the underlying status of a patient's fluid imbalance is essential for proper treatment and precision medicine.

"This research validates what we have pioneered — that our BVA system is the unique diagnostic tool that can bring essential data to clinicians, allowing for truly individualized patient care," said Michael Feldschuh, CEO and President of Daxor Corporation."

About Daxor Corporation

Daxor Corporation (Nasdaq: DXR) is tackling healthcare's "multi-billion-dollar silent crisis", the inability to precisely measure blood volume. This often results in suboptimal care, prolonged hospital stays, and increased readmissions for many high-cost medical conditions like heart failure and those requiring ICU care. With 50 years of experience and innovation, Daxor is proud to manufacture and distribute its patented, FDA-cleared Blood Volume Analysis (BVA) diagnostic which offers unmatched, real-time, precise data via its rapid, hand-held, lab-based system. This empowers clinicians to make individualized treatment decisions that significantly improve patient outcomes and deliver substantial efficiencies in value-based healthcare. Daxor is ISO certified and operates a U.S.-based, 20,000-square-foot state-of-the-art manufacturing facility, positioning the company for accelerated market expansion.

For more information, please visit our website at Daxor.com.

Sign up to receive news on Daxor’s innovative technology HERE.

Forward-Looking Statements

Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risks associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact
Bret Shapiro
COO – Head of Capital Markets
COREIR
516-222-2560
brets@coreir.com|www.coreir.com

FAQ

What did Daxor (DXR) report about albumin escape rates at SCCM 2026?

BVA recorded a median 20% per hour albumin escape rate in the studied cohort. According to Daxor, this direct measurement contrasted with uniformly low traditional clinical scores, indicating possible underdetection of capillary leak by those indices.

How does Daxor's BVA compare to capillary leak indexes for heart failure patients?

BVA provided superior mechanistic specificity versus common clinical scores for heart failure. According to Daxor, direct in-vivo AER measurement showed weak correlation with four common indices, suggesting those scores can miss non-inflammatory vascular leak.

What is the clinical significance of Daxor's SCCM 2026 data for DXR shareholders?

The data supports BVA as a unique diagnostic tool with potential market expansion into critical care and heart failure. According to Daxor, objective real-time leak and volume metrics strengthen the product's commercial differentiation and clinical utility.

Will Daxor's BVA replace traditional capillary leak scoring in practice?

BVA is presented as a complementary, more specific direct measurement, not an immediate replacement. According to Daxor, further studies are proposed to evaluate clinical scores in inflammatory leak versus BVA's direct AER measurement.

What future studies did Daxor propose after the SCCM 2026 presentation?

Future studies aim to test whether clinical scores are valid in inflammatory leak settings or if BVA remains the reliable direct metric. According to Daxor, proposed research will compare AER across inflammatory and non-inflammatory cohorts.